The thoracic oncology community is discussing the emerging role of perioperative immunochemotherapy in NSCLC, emphasizing the need for multidisciplinary case review as evidence grows. There is also commentary on the developing treatment landscape for HER2-mutated NSCLC, which accounts for approximately 3% of cases and has suboptimal second-line options with an overall survival of around 13.5 months.
“As we gather and establish more evidence for #neoadjuvant and #perioperative treatment, it is vital for cases to be discussed in a #multidisciplinary”
— @herbloong · Perioperative NSCLC · View post ↗📌 Amplified by @KolPulseAI
“HER2 #NSCL getting crowded with zongertinib, T-DXD, TDM1, sevabertinib”
— @mgonzalezvelMD · HER2 NSCLC landscape · View post ↗📌 Amplified by @KolPulseAI
“Take- ~3% of NSCLC. 2L treatments are suboptimal. OS of ~13.5 months can be improved.”
— @mgonzalezvelMD · HER2 NSCLC outcomes · View post ↗📌 Amplified by @KolPulseAI
Quiet today — no notable KOL discussion in the last 48 hours.
Quiet today — no notable KOL discussion in the last 48 hours.
The GU oncology community is discussing long-term follow-up data from two key trials. In advanced RCC, the OMNIVORE trial's results support discontinuing nivolumab in responding patients. For oligometastatic mCRPC, a long-term update from the ARTO trial demonstrated an overall survival benefit (HR 0.55) for adding SBRT to abiraterone and ADT.
“Can early responders to single-agent nivolumab safely stop? OMNIVORE's long-term data confirms current practice”
— @katy_beckermann · OMNIVORE trial in RCC · View post ↗
“🚨 ARTO long-term update in oligometastatic mCRPC: SBRT to all mets + abi/ADT vs abi/ADT alone.”
— @Adam_Weiner535 · ARTO trial in mCRPC · View post ↗📌 Amplified by @KolPulseAI
“discusses the determinants of immune response in RCC in this AKCI didactic lecture:”
— @brian_rini · Immune response in RCC · View post ↗The myeloma/hematology community is discussing a first-in-human phase I trial of BCMA PET imaging. In 50 patients, the agent 68Ga-PFBC01 demonstrated a sensitivity of 96.9% versus 84.6% for FDG-PET in myeloma, leading to changes in patient management.
“First-in-human BCMA PET: in a 50-patient phase I trial, 68Ga-PFBC01 beat FDG-PET in myeloma - sensitivity 96.9% vs 84.6% - and changed management.”
— @AtrashShebli · BCMA PET Imaging · View post ↗The hematology community is discussing evolving risk assessment and treatment approaches across several malignancies. Conversations in AML focus on new frontline therapy algorithms and the role of Menin-Inhibitors via the KOMET-007 trial. Other key topics include the evolution of risk assessment in CML and the prognostic significance of BCL2/BCL6 rearrangements in Follicular Lymphoma.
“from diagnosis to treatment-free remission, prognostic factors continue to shape clinical decision-making in CML.”
— @Haematologica · CML Risk Assessment · View post ↗
“FL3B w/ BCL6 rearrangement had a more aggressive course akin to DLBCL”
— @UyanikMehmetS · Follicular Lymphoma Prognosis · View post ↗
“Frontline AML therapy is rapidly evolving with targeted and lower-intensity options.”
— @TalhaBadarMD · Frontline AML Therapy · View post ↗
“Menin-Inhibitors are changing how we treat AML, and Amer discusses the paper and its implications.”
— @chadinabhan · AML Treatment · View post ↗